Gubra AS (CHIX:GUBRAC) Other Current Payables: kr0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GUBRAC Gubra AS CHIX:GUBRAC
78 GF Score
Price kr354.50
GF Value kr2,853.77
! 3 Warning Signs
View Full Analysis

What is Gubra AS Other Current Payables?

Gubra AS CHIX:GUBRAC 78 Other Current Payables is kr0 Mil as of Dec. 2025. GuruFocus rates CHIX:GUBRAC with a GF Score™ of 78/100 and a GF Value™ of kr2,853.77. The stock has 3 warning signs investors should review.

Gubra AS's Other Current Payables for the quarter that ended in Dec. 2025 was kr0 Mil.

Gubra AS's quarterly Other Current Payables increased from Dec. 2024 (kr0 Mil) to Jun. 2025 (kr1,000 Mil) but then declined from Jun. 2025 (kr1,000 Mil) to Dec. 2025 (kr0 Mil).

Gubra AS Other Current Payables Related Terms

Gubra AS Other Current Payables Historical Data

* Premium members only.

The historical data trend for Gubra AS's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gubra AS Other Current Payables Chart

Gubra AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Gubra AS Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 1,000.26 0.00
CHIX:GUBRAC
78GF Score
Gubra AS CHIX:GUBRAC
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gubra AS Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of kr0 Mil mean?
Gubra AS (CHIX:GUBRAC) has a Other Current Payables of kr0 Mil as of Dec. 2025. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gubra AS and its competitors.
Is Gubra AS's Other Current Payables too high?
Gubra AS's current Other Current Payables is kr0 Mil. Overall, Gubra AS has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Other Current Payables compare to VRTX and REGN?
Gubra AS's Other Current Payables of kr0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gubra AS and its competitors. Gubra AS's current Other Current Payables is kr0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Gubra AS (CHIX:GUBRAC) has a current Other Current Payables of kr0 Mil. The stock's GF Value™ is kr2,853.77, compared to a current price of kr354.50 — trading 87.6% below its estimated fair value. The current Other Current Payables is kr0 Mil. Gubra AS's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Gubra AS (CHIX:GUBRAC), the current Other Current Payables is kr0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gubra AS (CHIX:GUBRAC) Overvalued in 2026?

Based on GuruFocus' analysis, Gubra AS stock appears to be undervalued. The current stock price of kr354.50 is trading 87.6% below its estimated GF Value™ of kr2,853.77.

Key valuation signals for CHIX:GUBRAC:

  • Other Current Payables: kr0 Mil
  • GF Value™: kr2,853.77 vs. price of kr354.50 (87.6% below fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the CHIX:GUBRAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gubra AS Business Description

Other Exchanges GUBRA:DenmarkPI3:Germany
Address Horsholm Kongevej 11B, Horsholm, DNK, 2970
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
78GF Score

Get the complete analysis for CHIX:GUBRAC

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr354.50
Price
kr2,853.77
GF Value